Analyst Consensus ?
ConsensusBuy34 ratings
Bullish2573.5%
Neutral926.5%
Bearish00.0%
Labcorp Holdings Inc. · LH · FY2026 Q3 · Calendar Q4 2026
Labcorp raises 2026 outlook as Q3 growth broadens
Labcorp's Q3 analysis supports a constructive operating picture: revenue, EPS and margins improved, while specialty testing, biopharma services and acquisitions broadened growth. The main counterweight is reimbursement and integration risk.
Reported Before market openNYSEHealthcare
$26.86B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $4.64
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $3.76B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+8.8%
Event window
SPY move
+0.3%
Same window
Abnormal move
+8.4%
Stock minus SPY
Volume
2.8×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
LHSPY benchmark
Ask FN2 about LH FY2026 Q3
Transcript, numbers and history already loaded
What drove LH's +8.8% move after FY2026 Q3 earnings?What changed in LH's guidance and outlook in FY2026 Q3?Give me the bull and bear case for LH after FY2026 Q3 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported 7% Q3 revenue growth, 14.5% EPS growth and 60-basis-point margin expansion, and raised full-year 2026 revenue and EPS guidance. The company also highlighted new test clearances, partnerships and acquisitions.
Guidance delta
Guidance sentiment was raised. The supplied analysis says full-year 2026 enterprise revenue and EPS guidance increased; no revised ranges were supplied in the current analysis.
Key takeaways
- Specialty testing and biopharma services were identified as important growth drivers.
- Recent and planned offerings include pTau217, a hepatitis D reflex test and PlasmaDetect MRD.
- The proposed PAMA fee schedule could create a $125 million Medicare reimbursement impact in 2027.
Management priorities
- Expand specialty testing in oncology, neurology and women's health.
- Increase central-laboratory capacity and efficiency through Launchpad, automation and a new Indianapolis facility.
- Advance acquisitions, partnerships and new diagnostic offerings.
Follow LH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$360.25Current
$240Low
$314.32Average
$380High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Sep 21, 2026 |
| UBS | Buy | Buy | Maintain | Sep 11, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Sep 11, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 4, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Baird | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 13, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Oct 17, 2025 |
| Citigroup | Buy | Neutral | Upgrade | Mar 4, 2025 |
| Jefferies | Buy | Buy | Maintain | Feb 6, 2025 |
| HSBC | Buy | Hold | Upgrade | Oct 30, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 2, 2024 |
| Argus Research | Buy | Hold | Upgrade | Mar 25, 2024 |
| Wells Fargo | Overweight | Overweight | Maintain | Aug 14, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 2, 2023 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jul 13, 2020 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | May 21, 2020 |
| Keybanc | Overweight | Overweight | Maintain | Mar 30, 2020 |
| Bank of America | Neutral | Underperform | Upgrade | Jul 16, 2019 |
| Canaccord Genuity | Hold | Hold | Maintain | May 2, 2019 |
| Goldman Sachs | Buy | Conviction Buy | Downgrade | Nov 30, 2018 |
| Argus | Hold | Buy | Downgrade | Oct 30, 2018 |
| JMP Securities | Outperform | Market Outperform | Maintain | Mar 27, 2015 |
| Maxim Group | Buy | Buy | Maintain | Mar 24, 2015 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 23, 2015 |
| Raymond James | Outperform | Underperform | Upgrade | Jan 2, 2015 |
| FBR Capital | Market Perform | Market Perform | Maintain | Oct 28, 2014 |
| William Blair | Outperform | Market Perform | Upgrade | Jul 17, 2014 |
| Cantor Fitzgerald | Buy | Buy | Maintain | May 9, 2014 |
| ISI Group | Neutral | Neutral | Maintain | Nov 19, 2013 |
| Craig-Hallum | Buy | Buy | Maintain | Aug 28, 2013 |
| Oppenheimer | Perform | Perform | Maintain | Jan 28, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $360.25. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | David MacDonald | $365 | $320.71 | +1.3% | Sep 21, 2026 |
| UBS | Kevin Caliendo | $380 | $307.42 | +5.5% | Sep 11, 2026 |
| Barclays | Analyst unavailable | $330 | $306.96 | -8.4% | Sep 11, 2026 |
| Mizuho Securities | Ann Hynes | $355 | $319.17 | -1.5% | Aug 10, 2026 |
| Morgan Stanley | Analyst unavailable | $338 | $308.64 | -6.2% | Jul 31, 2026 |
| Deutsche Bank | Analyst unavailable | $306 | $308.7 | -15.1% | Jul 31, 2026 |
| Robert W. Baird | Analyst unavailable | $352 | $315.53 | -2.3% | Jul 31, 2026 |
| Barclays | Analyst unavailable | $320 | $315.82 | -11.2% | Jul 30, 2026 |
| Robert W. Baird | Eric Coldwell | $334 | $255.97 | -7.3% | May 1, 2026 |
| Evercore ISI | Analyst unavailable | $300 | $274.72 | -16.7% | Apr 8, 2026 |
| Piper Sandler | David Westenberg | $300 | $285.3 | -16.7% | Feb 24, 2026 |
| Robert W. Baird | Analyst unavailable | $326 | $276.67 | -9.5% | Feb 18, 2026 |
| Robert W. Baird | Analyst unavailable | $313 | $259.18 | -13.1% | Jan 14, 2026 |
| UBS | Kevin Caliendo | $320 | $253.74 | -11.2% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $304 | $259.69 | -15.6% | Oct 29, 2025 |
| Leerink Partners | Michael Cherny | $342 | $261.62 | -5.1% | Oct 28, 2025 |
| UBS | Analyst unavailable | $325 | $285.93 | -9.8% | Oct 17, 2025 |
| Mizuho Securities | Ann Hynes | $320 | $283.71 | -11.2% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $320 | $278.42 | -11.2% | Oct 14, 2025 |
| Evercore ISI | Analyst unavailable | $305 | $279.44 | -15.3% | Oct 3, 2025 |
| Barclays | Analyst unavailable | $290 | $279.06 | -19.5% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $311 | $276.11 | -13.7% | Aug 25, 2025 |
| UBS | Kevin Caliendo | $305 | $264.96 | -15.3% | Jul 25, 2025 |
| Barclays | Analyst unavailable | $275 | $258.7 | -23.7% | Jun 25, 2025 |
| Barclays | Luke Sergott | $271 | $247.86 | -24.8% | Feb 3, 2025 |
| Evercore ISI | Elizabeth Anderson | $240 | $224.72 | -33.4% | Sep 24, 2024 |
| Jefferies | Brian Tanquilut | $265 | $222.22 | -26.4% | Sep 23, 2024 |
| Bank of America Securities | Michael Ryskin | $260 | $236 | -27.8% | Aug 5, 2024 |
| Robert W. Baird | Eric Coldwell | $277 | $235.67 | -23.1% | Aug 2, 2024 |
| Argus Research | David Toung | $250 | $212.5 | -30.6% | Mar 25, 2024 |
| Morgan Stanley | Analyst unavailable | $303 | $241.42 | -15.9% | Jan 6, 2023 |
| Credit Suisse | Analyst unavailable | $305 | $238 | -15.3% | Nov 23, 2022 |
| Mizuho Securities | Analyst unavailable | $296 | $254.72 | -17.8% | Jul 29, 2022 |
| Deutsche Bank | Analyst unavailable | $265 | $245.45 | -26.4% | May 3, 2022 |
| Credit Suisse | Analyst unavailable | $312 | $240.28 | -13.4% | May 2, 2022 |
| Wells Fargo | Analyst unavailable | $315 | $266.12 | -12.6% | Apr 25, 2022 |
| Bank of America Securities | Derik de Bruin | $370 | $276.26 | +2.7% | Feb 11, 2022 |
| Deutsche Bank | Pito Chickering | $294 | $270.08 | -18.4% | Jan 28, 2022 |
| Truist Financial | David S Macdonald | $350 | $296.15 | -2.8% | Jul 30, 2021 |
| Argus Research | Jasper Hellweg | $295 | $269.61 | -18.1% | May 20, 2021 |
Track every rating change on LH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationLabcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
Historical context
All LH earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BIIB Biogen Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -3.4% | Biogen Q3: Growth portfolio expands as guidance rises |
| UHS Universal Health Services, Inc. | FY2026 Q3 · Calendar Q4 2026 | +0.6% | -2.9% | UHS reaffirms guidance as new-hospital ramps weigh on Q3 |
| GSK GSK plc | FY2026 Q3 · Calendar Q4 2026 | — | -4.3% | GSK reaffirms 2026 guidance as specialty medicines drive Q3 growth |
| BSX Boston Scientific Corporation | FY2026 Q3 · Calendar Q4 2026 | — | -3.5% | BSX Holds 2026 Guide Despite Cyber Hit and EP Pressure |
| AVTR Avantor, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -2.2% | Avantor reports stronger growth and raises full-year guidance |
| ICLR ICON Public Limited Company | FY2026 Q3 · Calendar Q4 2026 | — | +12.5% | ICON: bookings and margins improve as revenue dips |
Latest beats and misses
Who reports nextBeat on EPS
- CRFY2026 Q3 · October 27, 2026+12.6% EPS+2.9% move
- PPGFY2026 Q3 · October 27, 2026+6.1% EPS+4.4% move
- UMBFFY2026 Q3 · October 27, 2026+10.6% EPS-1.1% move
- UHSFY2026 Q3 · October 27, 2026+0.6% EPS-2.9% move
- ACGLNFY2026 Q3 · October 27, 2026+15.6% EPS-0.9% move
- RNRFY2026 Q3 · October 27, 2026+20.4% EPS-2.6% move
Get the LH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-28T16:05:27.575709+00:00
- FN2 earnings calendar · 2026-10-28T01:23:13.546025+00:00
- Polygon adjusted daily market bars · 2026-10-28T23:50:42.168394+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-28T23:50:42.165753+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-28. For educational purposes only; not investment advice.